2-[4-[(4,4 -Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Patent 4423049 Issued on December 27, 1983. Estimated Expiration Date:

December 28, 2001. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3398151

3717634

3907801

Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
Patent #: 3976776
Issued on: 08/24/1976
Inventor: Wu , et al.

Buspirone anti-anxiety method Patent #: 4182763
Issued on: 01/08/1980
Inventor: Casten , et al.

Inventor

Temple, Jr., Davis L.

Assignee

Mead Johnson & Company

Application

No. 06/334688 filed on 12/28/1981

US Classes:

514/252.18, Additional six-membered hetero ring consisting of five ring carbons and one ring nitrogen attached directly or indirectly to the 1,3-diazine by nonionic bonding544/230, Spiro544/231, Spiro diazine544/298, Chalcogen bonded directly to diazine ring carbon544/299, At 2-, 4-, and 6-positions (e.g., barbituric acid, etc.)544/309, At 2-position and at 4- or 6-position544/319, At 4- or 6-position544/360, Six-membered ring consisting of one nitrogen and five carbons (e.g., pyridine, etc.)544/389, The -C(=X)- is part of a -C(=X)X- group, wherein the X's are the same or diverse chalcogens546/243At 2-position

Examiners

Primary: Daus, Donald G.
Assistant: Turnipseed, James H.

Attorney, Agent or Firm

International Classes

C07C 51/00 (20060101)
C07D 239/00 (20060101)
C07D 211/00 (20060101)
C07D 211/88 (20060101)
C07D 239/56 (20060101)
C07D 211/90 (20060101)
C07D 239/46 (20060101)
C07D 239/42 (20060101)
C07D 309/32 (20060101)
C07D 309/00 (20060101)
C07D 401/00 (20060101)
C07D 401/12 (20060101)
C07D 487/00 (20060101)
C07D 487/10 (20060101)

Abstract

1-[4-(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]piperazines with 2-pyrimidyl substituents in the 4- position have been synthesized and demonstrate useful anxiolytic properties. The compound 4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedi one, which has selective anxiolytic activity, constitutes the preferred embodiment of the invention.